Clinical Trial · NCT02940262

Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial Therapy

Overview

This clinical trial studies how well gallium Ga 68-labeled prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) works in detecting prostate cancer that has come back (recurrent) in patients after initial therapy. Diagnostic procedures, such as gallium Ga 68-labeled PSMA-11 PET/CT, may help doctors detect tumors that have come back after initial therapy.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

Phase 3

Contacts

Johannes Czernin, MD (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT02940262

Drug / Compound

PSMA-11

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: HBED-CC

Eligibility

Inclusion

Histopathological proven prostate adenocarcinoma
Rising PSA after definitive therapy with prostatectomy or radiation therapy.
Nadir + greater than or equal to 2 ng/mL rise in PSA
Post-radiation therapy - American Society for Therapeutic Radiation and Oncology (ASTRO)-Phoenix consensus definition
Karnofsky performance status of \>= 50 (or Eastern Cooperative Oncology Group \[ECOG\]/ World Health Organization \[WHO\] equivalent)
Post radical prostatectomy (RP)
PSA equals to or greater than 0.2 ng/mL measured more than 6 weeks after RP

Exclusion

Known inability to lie flat, remain still or tolerate a PET scan
Concomitant investigational therapy
Patient undergoing active treatment for non-prostate malignancy, other than skin basal cell or cutaneous superficial squamous cell carcinoma that has not metastasized and superficial bladder cancer

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…